These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 4559814)

  • 1. Plasma endogenous triglyceride transport in hypertriglyceridaemia and effect of a hypolipidaemic drug (SU-13437).
    Nikkilä EA; Kekki M
    Eur J Clin Invest; 1972 Jun; 2(4):231-8. PubMed ID: 4559814
    [No Abstract]   [Full Text] [Related]  

  • 2. [Combination of clofibrate and phenformin in the treatment of endogenous hypertriglyceridaemia (author's transl)].
    Vogelberg KH
    Dtsch Med Wochenschr; 1976 Dec; 101(51):1868-71. PubMed ID: 1001205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transport kinetics of plasma free fatty acid, very low density lipoprotein triglycerides and apoprotein in patients with endogenous hypertriglyceridaemia: effects of 2,2-dimethyl, 5(2, 5-xylyoxy) valeric acid therapy.
    Kissebah AH; Alfarsi S; Adams PW; Seed M; Folkard J; Wynn V
    Atherosclerosis; 1976; 24(1-2):199-218. PubMed ID: 182185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglycerides in man.
    Kesäniemi YA; Grundy SM
    JAMA; 1984 May; 251(17):2241-6. PubMed ID: 6368883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Etofibrate and clofibrate in a double-blind trial on patients with raised serum-lipid levels (author's transl)].
    Kaffarnik H; Schneider J; Haase W
    Dtsch Med Wochenschr; 1975 Nov; 100(48):2486-8. PubMed ID: 1104303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypolipidemic effect of tibric acid. A comparison with clofibrate and placebo in type IV hyperlipoproteinemia.
    Bielmann P; Brun D; Moorjani S; Gagnon MA; Tétreault L; Lupien PJ
    Int J Clin Pharmacol Biopharm; 1977 Apr; 15(4):166-71. PubMed ID: 192685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacokinetics of clofibrate in uremic patients treated with dialysis. Effects of dietetic and drug therapy on triglycerides in the blood].
    Garini G; Vaona GL; Arisi L; Bignardi L; David S; Gaudiano V; Rossi E; Savazzi GM; Cambi V; Migone L
    Minerva Nefrol; 1979; 26(1):55-60. PubMed ID: 471323
    [No Abstract]   [Full Text] [Related]  

  • 8. Clofibrate raises plasma apoprotein A-I and HDL-cholesterol concentrations.
    Nestel PJ; Hunt D; Wahlqvist ML
    Atherosclerosis; 1980 Dec; 37(4):625-9. PubMed ID: 7459005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of clofibrate with halofenate in diabetics with hyperlipidaemia.
    Krut LH; Seftel HC; Joffe BI
    S Afr Med J; 1977 Mar; 51(11):348-52. PubMed ID: 323994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A clofibrate controlled trial of gemfibrozil in the treatment of hyperlipidaemias.
    Tuomilehto J; Salonen J; Kuuisto P; Virtamo J; Manninen V; Mälkönen M
    Proc R Soc Med; 1976; 69 Suppl 2(Suppl 2):38-40. PubMed ID: 798195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparative studies on the cholesterol and triglyceride-lowering effect of alpha-methylthyroxine (Skleronorm) and clofibrate (Regelan) in hyperlipoproteinemias of type IIa/b and IV].
    Jantke J; Schwartzkopff W; Zschiedrich M
    Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():392-5. PubMed ID: 206057
    [No Abstract]   [Full Text] [Related]  

  • 12. The mechanism of action of clofibrate and tetranicotinoylfructose (Bradilan) on the kinetics of plasma free fatty acid and triglyceride transport in type IV and type V hypertriglyceridaemia.
    Kissebah AH; Adams PW; Harrigan P; Wynn V
    Eur J Clin Invest; 1974 Jun; 4(3):163-74. PubMed ID: 4838694
    [No Abstract]   [Full Text] [Related]  

  • 13. Control of clofibrate toxicity in uremic hypertriglyceridemia.
    Goldberg AP; Sherrard DJ; Haas LB; Brunzell JD
    Clin Pharmacol Ther; 1977 Mar; 21(3):317-25. PubMed ID: 837651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationship between insulin secretion and triglyceride concentration in endogenous lipemia.
    Eaton BP; Nye WH
    J Lab Clin Med; 1973 May; 81(5):682-95. PubMed ID: 4349136
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparative hypolipidaemic effectiveness of gum guggulu (Commiphora mukul) fraction 'A', ethyl-P-chlorophenoxyisobutyrate and Ciba-13437-Su.
    Malhotra SC; Ahuja MM
    Indian J Med Res; 1971 Oct; 59(10):1621-32. PubMed ID: 5159000
    [No Abstract]   [Full Text] [Related]  

  • 16. Chenodeoxycholic acid therapy for hypertriglyceridaemia in men.
    Bateson MC; Maclean D; Evans JR; Bouchier IA
    Br J Clin Pharmacol; 1978 Mar; 5(3):249-54. PubMed ID: 656270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of clofibrate in hyperlipidemia: a controlled trial.
    Ilyas M; Peracha MA; Ali N; Husnain Sherazi SM; Mahmood N
    J Pak Med Assoc; 1978 Sep; 28(9):126-8. PubMed ID: 105169
    [No Abstract]   [Full Text] [Related]  

  • 18. One-year trials with halofenate, clofibrate, and placebo.
    Dujovne CA; Azarnoff DL; Huffman DH; Pentikäinen P; Hurwitz A; Shoeman DW
    Clin Pharmacol Ther; 1976 Mar; 19(3):352-9. PubMed ID: 177242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clofibrate in type II hyperlipoproteinemia.
    Ditzel J; Bang HO
    Acta Med Scand; 1976; 200(1-2):55-58. PubMed ID: 183462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of obesity on the relationship between insulin and triglyceride levels in endogenous hypertriglyceridemia.
    Bagdade JD; Bierman EL; Porte D
    Diabetes; 1971 Oct; 20(10):664-72. PubMed ID: 5110698
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.